Shots:
- Novartis has reported the P-III (APPLAUSE-IgAN) trial findings assessing Fabhalta (200mg; BID; PO) vs PBO, both on top of SoC in 477 adults with IgA nephropathy (IgAN)
- Trial showed that Fabhalta reduced IgAN progression measured by annualized total slope of eGFR decline over 2yrs., & demonstrated favorable safety; data to be used for 2026 submissions & presented at future meetings
- Novartis is also investigating Vanrafia (atrasentan; endothelin A receptor antagonist, PO) & zigakibart (anti-APRIL mAb, SC) for treating IgAN
Ref: Novartis | Image: Novartis | Press Release
Related News:- Novartis’ Rhapsido (Remibrutinib) Receives the US FDA’s Approval for Chronic Spontaneous Urticaria
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
